Prostaglandin F2a CAS NO.551-11-1

Prostaglandin F2α (PGF2α) is present in numerous species and has a widespread distribution. It can cause smooth muscle contraction in the vascular, bronchial, intestinal, and myometrial regions, and has potent luteolytic activity. PGF2α exerts its physiological effects through receptor mediation, with maximal ovine myometrial contraction being achieved at 125 nM PGF2α in vitro, and its receptor-mediated activity is most potent at 50-100 nM. Studies have also shown that PGF2α inhibits nitric oxide production in uterine tissue, enhances uterine contractility, and exhibits potent luteolytic activity. Furthermore, PGF2α functions as an activator of PGF2α

Prostaglandins (PGs) are a class of important endogenous products with a wide range of physiological activities. PGs were first discovered and named by American scholar Von Eluer in 1930. In 1962, Bergstorm extracted two pure PGs (PGF1 and PGF2) and determined their chemical structures. In 1969, Willis first proposed that PGs are an inflammatory mediator in the body. Subsequently, various physiological and pharmacological activities of PGs have been intensively studied.